Members of the opioid receptor family of G-protein-coupled receptors (GPCRs) are found throughout the peripheral and central nervous system, where they have key roles in nociception and analgesia. Unlike the 'classical' opioid receptors, d, k and m (d-OR, k-OR and m-OR), which were delineated by pharmacological criteria in the 1970s and 1980s, the nociceptin/orphanin FQ (N/OFQ) peptide receptor (NOP, also known as ORL-1) was discovered relatively recently by molecular cloning and characterization of an orphan GPCR 1 . Although it shares high sequence similarity with classical opioid GPCR subtypes ( 60%), NOP has a markedly distinct pharmacology, featuring activation by the endogenous peptide N/OFQ, and unique selectivity for exogenous ligands 2,3 . Here we report the crystal structure of human NOP, solved in complex with the peptide mimetic antagonist compound-24 (C-24) (ref. 4), revealing atomic details of ligand-receptor recognition and selectivity. Compound-24 mimics the first four aminoterminal residues of the NOP-selective peptide antagonist UFP-101, a close derivative of N/OFQ, and provides important clues to the binding of these peptides. The X-ray structure also shows substantial conformational differences in the pocket regions between NOP and the classical opioid receptors k (ref. 5) and m (ref. 6), and these are probably due to a small number of residues that vary between these receptors. The NOP-compound-24 structure explains the divergent selectivity profile of NOP and provides a new structural template for the design of NOP ligands.
Members of the opioid receptor family of G-protein-coupled receptors (GPCRs) are found throughout the peripheral and central nervous system, where they have key roles in nociception and analgesia. Unlike the 'classical' opioid receptors, d, k and m (d-OR, k-OR and m-OR), which were delineated by pharmacological criteria in the 1970s and 1980s, the nociceptin/orphanin FQ (N/OFQ) peptide receptor (NOP, also known as ORL-1) was discovered relatively recently by molecular cloning and characterization of an orphan GPCR 1 . Although it shares high sequence similarity with classical opioid GPCR subtypes ( 60%), NOP has a markedly distinct pharmacology, featuring activation by the endogenous peptide N/OFQ, and unique selectivity for exogenous ligands 2, 3 . Here we report the crystal structure of human NOP, solved in complex with the peptide mimetic antagonist compound-24 (C-24) (ref. 4) , revealing atomic details of ligand-receptor recognition and selectivity. Compound-24 mimics the first four aminoterminal residues of the NOP-selective peptide antagonist UFP-101, a close derivative of N/OFQ, and provides important clues to the binding of these peptides. The X-ray structure also shows substantial conformational differences in the pocket regions between NOP and the classical opioid receptors k (ref. 5 ) and m (ref. 6) , and these are probably due to a small number of residues that vary between these receptors. The NOP-compound-24 structure explains the divergent selectivity profile of NOP and provides a new structural template for the design of NOP ligands.
The pharmacological effects of NOP are complex and distinct from classical opioid receptors. N/OFQ shares sequence similarity with other opioid peptides, notably the k-OR endogenous ligand dynorphin A, but does not interact with d-OR, k-OR or m-OR. Similarly, the classical opioid peptides have very low affinity for NOP. Unlike the classical opioid receptors, NOP is also insensitive to most morphinelike small molecules including naloxone, thereby yielding a pharmacologically important discriminatory feature between NOP and classical opioid receptors. Studies with N/OFQ, NOP-selective agonists or antagonists, and receptor-or peptide-deficient mice have shown that the NOP system has important roles in the control of central and peripheral functions including pain, anxiety and mood, food intake, learning and memory, locomotion, cough and micturition reflexes, cardiovascular homeostasis, intestinal motility and immune responses 7 . Understanding the structural requirements for NOP ligand selectivity and modes of binding is therefore paramount for the optimization of future agonist-and antagonist-based therapeutics.
The 3.0 Å resolution X-ray crystal structure of the human NOP receptor in complex with C-24 was determined by replacing 43 N-terminal residues of the receptor with thermostabilized apocytochrome b 562 RIL (BRIL) 8 , and by truncating 31 carboxy-terminal residues of NOP ( Fig. 1a ) (see Methods). We found that this BRIL-NOP fusion is functional and responds to N/OFQ and the small molecular agonist SCH-221510 (ref. 9), activating endogenous heterotrimeric G i /G o proteins in HEK293T cells, albeit with reduced potency and efficacy (Supplementary Tables 2 and 3) , perhaps owing to the C-terminal NOP truncation. C-24 was selected for co-crystallization on the basis of the pronounced thermostability it imparts on the receptor ( Supplementary Fig. 1 ), its high affinity (half-maximum inhibitory concentration (IC 50 ) 5 0.27 nM) and antagonist potency (IC 50 5 0.1 nM) for NOP, and its selectivity ($1,000-fold) 4 . Peripherally administered C-24 is able to penetrate the central nervous system, where it antagonizes N/OFQ effects on nociception 10 and produces beneficial responses in experimental models of Parkinson's disease 11 . The NOP structure revealed C-24 binding deep within the orthosteric binding pocket ( Fig. 1a ), probably mimicking the 'message' domain of N/OFQ (Phe 1-Gly 2-Gly 3-Phe 4), a similar sequence to that of canonical opioid peptides (Tyr 1-Gly 2-Gly 3-Phe 4) 7,12 (Supplementary Fig. 2 ).
Structural comparison of published GPCR crystal structures shows a modularity of the seven-transmembrane helical core, and considerable variation of the extracellular module with boundaries defined by proline-induced kinks 13 . NOP contains five such kinks in the seventransmembrane core located at residue positions Pro 105 2.58 , Pro 184 4.59 , Pro 227 5.50 , Pro 278 6.50 and Pro 316 7.50 (superscripts indicate residue numbers as per the Ballesteros-Weinstein nomenclature 14 ), yielding repercussions on the shape of the ligand-binding pocket. Notably, the extracellular tip of helix V in NOP is shifted by more than 4 Å as compared with the k-OR 5 and m-OR 6 crystal structures (Protein Data Bank (PDB) accessions 4DJH and 4DKL, respectively), thereby resulting in both a gap between helices IV and V (,12 Å between Ca of residues 184 and 215) and an expansion of the orthosteric pocket ( Supplementary Fig. 5 ). However, compared with the chemokine receptor CXCR4, the extracellular tip of helices VI and VII are tilted inwards, towards the orthosteric pocket. Unlike the k-OR structure 5 , the extracellular half of helix I in NOP is pulled in towards the axis of the seven-transmembrane bundle, in a conformation that is more similar to that of the chemokine receptor (PDB accession 3ODU (ref. 15); Fig. 1b ). This alternative conformation of helix I is facilitated by the presence of flexible glycine residues located at an apparent 'hinge point' that are conserved within the opioid receptor family: Gly 65 1.46 and Gly 68 1.49 in NOP, and Gly 73 1.46 and Gly 76 1.49 in k-OR. NOP has an extra glycine at the hinge point, Gly 64 1.45 , adding to the potential flexibility of this helix.
Despite low sequence conservation, extracellular loops (ECLs) 1 and 2 of NOP are structurally similar to those of k-OR and CXCR4 ( Fig. 1b) . Specifically, the backbone of ECL1 in NOP is nearly indistinguishable from that of k-OR and CXCR4. ECL2 forms an elongated b-hairpin, which is tethered to the extracellular tip of helix III by a structurally conserved disulphide bond between Cys 123 3.25 and Cys 200 ECL2 . This b-hairpin motif is also observed in k-OR and CXCR4, suggesting a common structural motif of the c-branch 16 class A peptide-binding receptors. Unlike d-OR and m-OR, the ECL2s of k-OR and NOP are enriched in aspartate and glutamate residues, making the loops and the entrance to their binding pocket very acidic ( Supplementary Fig. 6 ). Moreover, ECL2 in NOP is two residues shorter than in k-OR, making it and differences in charge distribution possible determinants for selectivity. These details are consistent with N/OFQ-dynorphin A chimaera peptide data showing that replacement of six residues on the address domain of N/OFQ with the corresponding residues from dynorphin A markedly impaired affinity and activity towards NOP 17 .
Intracellular loop (ICL) 2 of NOP receptor molecule 'B' in the asymmetric unit forms a short a-helix, which has been observed in many other GPCRs (Fig. 1c) ; the ICL2 is tethered to the seventransmembrane core via a salt bridge between Arg 162 ICL2 found in all opioid receptors and Asp 147 3.49 from the conserved 'D(E)RY' motif ( Supplementary Fig. 7 ). The ICL3 connecting helices V and VI is thought to be highly malleable as it accommodates activation-related rearrangements in these helices and binding of heterotrimeric G i /G o proteins. Therefore, the structure of ICL3 found in the NOP receptor molecule 'A', which has 15 residues in a coil conformation and a hydrogen bond between the backbone carbonyl of Val 245 ICL3 and the Arg 259 6.31 side chain, is probably just one of the possible configurations the loop can adopt. Structural alignment with thermostabilized A 2A AR (PDB accession 3PWH) 18 also suggests dissimilarity in the ICL3 regions of these receptors, where NOP helices V and VI are shorter and further apart than in A 2A AR, and the coiled part of ICL3 is longer than A 2A AR (15 residues in NOP versus 8 residues in A 2A AR) ( Fig. 1c and Supplementary Fig. 7) .
The NOP-C-24 structure highlights specific residues in the pocket that are essential for N/OFQ binding and receptor subtype selectivity (Fig. 2 ). The orthosteric binding pocket of NOP is relatively large, reflecting its ability to bind large endogenous peptides. With a similar pose in both NOP molecules (root mean squared deviation (r.m.s.d.) 5 0.6 Å ), C-24 interacts with the 'floor' of the pocket through several hydrophobic and electrostatic interactions. Mutagenesis of the binding pocket of NOP defined the relative impact of specific residues on C-24 and N/OFQ binding and function ( Supplementary Tables 4  and 5 ). The protonated nitrogen of the C-24 piperidine ring forms a crucial salt bridge with Asp 130 3.32 -a residue that is conserved in the opioid receptor family and all biogenic amine GPCRs. Mutations of Asp 130 3.32 to either alanine or asparagine abrogate N/OFQ binding, highlighting the requirement of the negative charge at this position 19 ( Fig. 2 and Supplementary Tables 4 and 5) , and it has been proposed that Asp 130 3.32 is involved in a salt-bridge interaction with the positively charged N-terminal nitrogen of N/OFQ 20, 21 . In addition to the anchoring salt bridge between Asp 130 3.32 and the amino moiety of C-24, the linked benzofuran/piperidine rings are buried in a hydrophobic pocket created by residues from helices III, V and VI. The benzofuran 'head' group is sandwiched between Met 134 3.36 and Tyr 131 3.33 , in which the Met 3.36 side chain adopts a different, more buried rotamer as compared to k-OR, thereby allowing a deeper penetration of the C-24 ring system. This is consistent with the modest effect of a Met 134 3.36 Ala mutation on the potency of NOP ligands ( Supplementary Tables 4 and 5) . A Tyr 131 3.33 Phe mutation had no effect on agonist binding, whereas Tyr 131 3.33 Ala was deleterious ( Supplementary Tables 4 and 5 ), suggesting that Tyr 131 participates in p-stacking interactions with Phe 1 of the peptide 19 .
At the 'tail' end of C-24, the carbonyl group adjacent to the pyrrolidine ring is hydrogen bonded to Gln 107 2.60 , a residue stabilized by a hydrogen bond to Tyr 309 7.43 . A Gln 107 2.60 Ala mutation results in a 10-fold loss in C-24 binding and a more than 300-fold reduction in N/OFQ potency, and mutation of Tyr 309 7.43 abolishes binding of C-24 and reduces N/OFQ potency ,7-fold (Supplementary Tables 4 and 5) . Interestingly, both Gln 2.60 and Tyr 7.43 are present in the k-OR structure, albeit in very different conformations ( Supplementary Fig. 8 ).
The crystal structure of NOP in complex with C-24 afforded us a unique opportunity to determine the molecular basis for both the high-affinity binding by N/OFQ-derived peptide antagonists and their pronounced subtype selectivities ( Fig. 3 ). Notably, we verified that the C-24 binding mode can be reliably reproduced by energy-based docking of C-24 to the NOP receptor, with an r.m.s.d. of ,0.9 Å . Moreover, docking of another piperidine derivative, compound-35 (C-35) 22 , closely mimics the binding of C-24, whereas docking of a less active stereoisomer compound-36 (ref. 22 ) yields a considerably distorted binding pose in the pyrrolidine region and a reduced binding score (not shown). C-24 has previously been proposed 22 to mimic the N-terminal four residues of N/OFQ-related peptide antagonists [Nphe 1]N/OFQ(1-13)-NH 2 (in which Nphe denotes N-benzylglycine) 23 and UFP-101 (ref. 24) . Automated docking of the four N-terminal residues of UFP-101 results in a conformation of the Nphe 1-Gly 2-Gly 3-Phe 4 tetrapeptide in which the Nphe 1 and Phe 4 rings of the peptide make the same hydrophobic interactions as the aromatic rings of C-24, and the N-terminal amino group forms a salt bridge with Asp 130 3.32 , thus supporting the proposed similarity in the binding poses between small molecules and peptide analogues (Fig. 3c) .
The 'address' domain of N/OFQ (residues 5-17) was previously shown by NMR to have a strong preference for a-helical secondary structure 25, 26 , which is probably preserved in UFP-101 as the only difference in this domain are the mutations Leu14Arg and Ala15Lys. Docking of the full-length UFP-101 suggests a plausible fit of the a-helical address domain into the binding pocket entrance shaped in ribbon representation with its ECL2 highlighted (red). The bound ligand C-24 is depicted as green spheres, and transparent disks highlight the extracellular (EC) and intracellular (IC) membrane boundaries (coloured blue and red, respectively). b, Structural superposition of NOP molecules 'A' and 'B', k-OR (PDB accession 4DJH) 5 and CXCR4 (PDB accession 3ODU) 15 , coloured grey, yellow, blue and orange, respectively. Compared with k-OR, the extracellular portion of helix I from NOP is tilted inwards towards the orthosteric pocket, in a similar conformation to CXCR4. c, Structural superposition of NOP molecules A and B and thermostabilized A 2A AR (PDB accession 3PWH) 18 , coloured grey, yellow and green, respectively, highlighting conformational differences between the ICLs.
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by the highly acidic tip of ECL2 and helices II and VII, with all six basic residues of the peptide forming ionic interactions with acidic side chains of NOP ( Fig. 3c-e ).
Interactions of the address domain of N/OFQ(1-13) with helices II (residues 107-113) 27 and VII (residues 296-302) 19 were previously demonstrated by photocrosslinking, a finding consistent with our mutagenesis data showing the crucial importance of Asp 110 2.63 in the binding of N/OFQ but not small molecule antagonists or the agonist SCH-221510 (Supplementary Table 5 ). These results suggest a similar binding mode for the address domains of N/OFQ-derived peptides. On the other hand, note that the k-OR-binding peptide dynorphin A has a Pro 10 in the middle of the address sequence 12 that is unfavourable for a-helix formation, suggesting potential differences in the binding mode for this classical opioid peptide.
As mentioned earlier, NOP displays markedly reduced affinities for morphine-based small molecules and the classical opioid receptor peptide ligands: N/OFQ contains an N-terminal FGGF instead of the YGGF motif found in the classical opioid receptor peptide ligands. Previous biochemical studies attributed this distinct selectivity profile to the three residue positions in the binding pocket of NOP that differ from all other opioid receptors: Ala 216 5.39 (Lys in others), Gln 280 6.52 (His in others) and Thr 305 7.39 (Ile in others). Mutation of these three positions on the N/OFQ receptor to classical opioid receptor residues has been shown to be sufficient for conferring high-affinity binding to a dynorphin-derived k-OR selective peptide 28, 29 . Moreover, the same three mutations conferred nanomolar-range NOP binding of morphine-based opioid antagonists such as bremazocine, naltrexone and naltrindole, as well as a k-OR specific antagonist norbinaltorphimine (nor-BNI) 29 . The crystal structures of NOP and k-OR show that the side chains of these three residues are pointing towards the interior of the binding pocket ( Fig. 4 and Supplementary Fig. 8 ). In NOP, Gln 280 6.52 and Thr 305 7.39 are involved in C-24 interactions, and all three of the cognate residues at these positions are involved in k-OR interactions with the selective antagonist JDTic and with the modelled nor-BNI antagonists 5 . Notably, although most of the modified side chains are polar, none form direct hydrogen bonding interactions to the ligands tested, so that the selectivity profiles cannot be explained by simple polar-to-hydrophobic (or vice versa) changes of ligand contacts. Instead, a comparison of the NOP and k-OR structures shows that several of the NOP-specific side-chain changes, including two of the substitutions mentioned earlier (Ala 5.39 Lys and Gln 6.52 His), are involved in a large-scale reshaping of the binding pocket and an alternative coordination of water molecules (Fig. 4) . Located closer to the ligand-binding pocket entrance, Lys 227 5.39 in k-OR, and potentially in other classical opioid receptors, is involved in salt bridges with the side chains of Asp 223 5.35 and Glu 297 6.58 (Fig. 4a ). Replacement of Lys 5.39 to alanine in NOP precludes these stabilizing ionic interactions and is accompanied by an outwards shift of the extracellular half of helix V in the NOP crystal structure, and an inwards shift of helix VI. Opioid receptor subtype alteration of the large Lys 5.39 side chain and the accompanying shifts of the a-helices reshape the entrance to the pocket, and this probably affects the binding of address domains of peptides and synthetic ligands.
The k-OR structure reveals a cluster of water molecules that is coordinated by two of the classical opioid receptor-specific residues involved in binding pocket remodelling (Fig. 4b) in an approximately 10-fold decrease in affinity; green-labelled residues slightly increase the affinity of C-24; blue-labelled residues were not tested. Asp 110 had no effect on the binding of C-24, although it is crucial for N/OFQ binding.
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backbone carbonyl of Lys 227 5.39 . Interestingly, one such tightly bound water molecule is coordinated by His 6.52 and seems to preclude a buried rotamer conformation of Met 3.36 in k-OR that is observed in NOP, resulting in a deviation of more than 6 Å among the Ce atoms of the side chain in these two crystal structures (Fig. 4c ). This Met 3.36 residue is conserved in all opioid receptors and makes extensive hydrophobic interactions with the corresponding ligands in both NOP and k-OR. As a consequence, the 7-hydroxyisoquinoline head group of the k-OR ligand JDTic is not able to penetrate as deeply into this area of the orthosteric pocket as compared with the benzofuran group of C-24. The 'reoriented' hydroxylated head group of JDTic is stabilized by a hydrogen bond interaction to a water molecule that is coordinated by the backbone carbonyl of Lys 227 5.39 , potentially explaining the need for a tyrosine residue at the N terminus of dynorphin A. With modifications of Lys 5.39 to Ala 5.39 and His 6.52 to Gln 6.52 in the NOP receptor, remodelling of the binding pocket that includes a backbone shift in helix V, repacking of the Met 3.36 side chain and water rearrangements provides a likely explanation for selectivity in the message domain of the peptide ligands. Perhaps most intriguing are the evolutionary differences between NOP and the other three classical opioid receptors (k-OR, m-OR and d-OR). Despite high sequence identity between receptors, marked differences in ligand selectivity between these opioid receptors go in hand with substantial changes in the structure of their binding pockets. This situation is very different from other GPCR subfamilies (for example, b-adrenergic and muscarinic) in which different subtypes signal by the same ligands via highly conserved orthosteric pocket architectures. With structural data for k-OR 5 , m-OR 6 and NOP now available, and the fourth (d-OR) opioid receptor structure likely to come in the near future, one can begin to investigate the ligand structure activity relationships and evolutionary aspects of this receptor subfamily in greater detail. 
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METHODS SUMMARY
BRIL-NOP was expressed in Spodoptera frugiperda (Sf9) insect cells. Ligandbinding asays were performed as described in Methods. Sf9 membranes were solubilized using 0.5% (w/v) n-dodecyl-b-D-maltopyranoside and 0.1% (w/v) cholesteryl hemisuccinate, and purified by immobilized metal ion affinity chromatography. Receptor crystallization was performed by the lipidic cubic phase (LCP) method. The protein-LCP mixture contained 40% (w/w) concentrated receptor solution, 54% (w/w) monoolein and 6% (w/w) cholesterol. Crystals were grown in 40 nl protein-laden LCP bolus overlaid by 0.8 ml of precipitant solution (25-30% (v/v) PEG400, 100-200 mM potassium sodium tartrate tetrahydrate, 100 mM Bis-Tris propane, pH 6.4) at 20 uC. Crystals were collected directly from the LCP matrix and flash frozen in liquid nitrogen. X-ray diffraction data were collected at 100 K on the 23ID-B/D beamline (GM/CA-CAT) of the Advanced Photon Source at the Argonne National Laboratory using a 10-mm collimated minibeam. Diffraction data from 23 crystals were merged for the final data set. Data collection, processing, structure solution and refinement are described in Methods. Flexible docking of small molecules and peptides was performed with the ICM molecular modelling package (Molsoft LLC).
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
METHODS
Cloning, expression and purification. NOP contains a ,50-amino-acid extracellular domain at its N terminus, with a relatively high content of leucine and proline residues (26% and 14%, respectively) and three putative N-linked glycosylation sites. Despite high thermostability in the presence of select small molecule compounds, numerous attempts at crystallizing the receptor with an intact N terminus were unsuccessful. Although deletion of the C terminus (NOP-DC; 31amino-acid deletion) resulted in increased expression, any truncation of the N terminus decreased the expression levels. However, replacement of the N terminus with several soluble fusion proteins restored the expression to levels that were comparable with constructs containing a full N terminus. Fusion with the thermostabilized apocytochrome b 562 RIL (BRIL) 8 resulted in a construct (BRIL-DN-NOP-DC; referred to as BRIL-NOP in the manuscript) that was crystallized to 3.0 Å resolution in complex with the non-peptide antagonist C-24 (Banyu Pharmaceuticals). The wild-type human NOP gene (encoded by OPRL1; UniProt accession P41146) was synthesized by DNA2.0 with codon optimization for Spodoptera frugiperda (Sf9), and then cloned into a modified pFastBac1 vector (Invitrogen) containing an expression cassette with a haemagglutinin signal sequence followed by a Flag tag at the N terminus, and a PreScission protease site followed by a 103His tag at the C terminus. Thirty-one amino acids were deleted from the C terminus (residues 341-370), and 43 residues of the N terminus (residues 1-43) of NOP were replaced with the thermostabilized apocytochrome b 562 RIL from Escherichia coli (M7W, H102I and K106L) (BRIL) protein using splicing by overlap extension PCR 30 . Recombinant baculoviruses were generated using the Bac-to-Bac system (Invitrogen) and were used to infect Sf9 insect cells at a density of 2 3 10 6 cells ml 21 at a multiplicity of infection of 5. Infected cells were grown at 27 uC for 48 h before being collected, and the cell pellets were stored at 280 uC.
Insect cell membranes were disrupted by dounce homogenization of cell pellets in a hypotonic buffer containing 25 mM HEPES, pH 7.5, 10 mM MgCl 2 , 20 mM KCl and protease inhibitor cocktail (Roche). Extensive washing of the membranes was performed consecutively by repeated dounce homogenization and centrifugation in the same hypotonic buffer (approximately once more), followed by high osmotic buffer containing 1.0 M NaCl, 10 mM MgCl 2 , 20 mM KCl and 25 mM HEPES, pH 7.5 (three to four times). Purified membranes were resuspended in 500 mM NaCl, 20 mM KCl, 50 mM HEPES, pH 7.5, and 35% (v/v) glycerol, flash frozen with liquid nitrogen, and stored at 280 uC until further use.
Purified membranes were thawed and incubated with 25 mM C-24 (1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4'-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide) 4 (synthesized by C. Trapella and R. Guerrini), 500 mM NaCl, 20 mM KCl, 50 mM HEPES, pH 7.5, and 5% glycerol (v/v), and incubated at 4 uC for 1 h. Iodoacetamide (Sigma) was then added to the membranes at a final concentration of 1 mg ml 21 for another 15 min before solubilization with 0.5% (w/v) n-dodecyl-b-Dmaltopyranoside (DDM; Anatrace), and 0.1% (w/v) cholesteryl hemisuccinate (CHS; Anatrace or Sigma) for 3 h at 4 uC. The supernatant was isolated by centrifugation at 160,000g for 45 min, supplemented with 25 mM imidazole, pH 7.5, and incubated with TALON metal ion affinity chromatography resin (Clontech) overnight at 4 uC. Typically, 0.75 ml of resin (slurry) per 1 l of original culture volume was used. After binding, the resin was washed with 15 column volumes of wash buffer 1 (500 mM NaCl, 20 mM KCl, 10 mM MgCl 2 , 50 mM HEPES, pH 7.5, 5% (v/v) glycerol, 1 mM ATP, 25 mM imidazole, 25 mM C-24, 0.05% (w/v) DDM and 0.01% (w/v) CHS); and 5 column volumes of wash buffer 2 (same as wash buffer 1, but without ATP and MgCl 2 ), before protein elution with elution buffer (500 mM NaCl, 20 mM KCl, 50 mM HEPES, pH 7.5, 10% (v/v) glycerol, 250 mM imidazole, 25 mM C-24, 0.025% (w/v) DDM and 0.005% (w/v) CHS). Purified receptor was exchanged into a buffer containing 500 mM NaCl, 20 mM KCl, 5% (v/v) glycerol, 50 mM HEPES, pH 7.5, and 25 mM C-24 using a PD midiTrap G-25 column (GE Healthcare). BRIL-DN-NOP-DC was then supplemented with C-24 to a final concentration of 100 mM, and concentrated from ,0.4 mg ml 21 to 40 mg ml 21 with a 100-kDa molecular mass cut-off Vivaspin concentrator (GE Healthcare). Receptor purity and monodispersity was followed using SDS-PAGE and analytical size exclusion chromatography. Pharmacological assays. The different NOP constructs (codon optimized for Sf9 expression) were cloned from pFastBac into pCDNA3.1 and expressed in HEK293T cells. Mutations (Q107A, D110A, D130A, Y131A, M134A, I219A, Q280A and Y309A) were introduced into the NOP sequence using standard QuikChange protocols. Binding affinity was determined from competition binding assays using 3 H-N/OFQ as a radioligand. NOP receptor-mediated inhibition of the cyclic AMP response was measured using a cAMP biosensor (see ref. 31 for details) to assess the functionality of the NOP constructs and the effects of alanine mutations within 3.5 Å from the antagonist C-24 in the structure. HEK293T cells were transiently transfected for binding assays or functional assays. Antagonist inhibition response curves were measured in the presence of a concentration of agonist (N/OFQ or SCH-221510) approximately corresponding to its EC 80 value (the concentration that leads to an 80% maximum response). Results were analysed using GraphPad Prism. Crystallization. Protein samples of BRIL-DN-NOP-DC (concentrated to 40 mg ml 21 ) in complex with C-24 were reconstituted into the lipidic cubic phase (LCP) by mixing with molten lipid using a mechanical syringe mixer 32 . The protein-LCP mixture contained 40% (w/w) protein solution, 54% (w/w) monoolein (Sigma) and 6% (w/w) cholesterol (AvantiPolar Lipids). Crystallization trials were performed in 96-well glass sandwich plates 33 (Marienfeld) by the NT8-LCP (Formulatrix) or mosquito LCP (TTP LabTech) crystallization robots using 40 nl protein-laden LCP bolus overlaid with 0.8 ml precipitant solution in each well, and sealed with a glass coverslip. Protein reconstitution in LCP and crystallization trials were carried out at room temperature (,20-22 uC). The crystallization plates were stored and imaged in an incubator/ imager (RockImager 1000, Formulatrix) at 20 uC. Diffraction quality crystals of an average size of 40 3 10 3 3 mm were obtained within ,14 days in 25-30% (v/v) PEG400, 100-200 mM potassium sodium tartrate tetrahydrate, 100 mM Bis-Tris propane, pH 6.4. Crystals were collected directly from LCP using 50 mm MiTeGen micromounts and immediately flash frozen in liquid nitrogen without adding extra cryoprotectant. X-ray data collection and processing. Crystallographic data were collected on the 23ID-B/D beamline (GM/CA CAT) of the Advanced Photon Source at the Argonne National Laboratory, using a 10 mm collimated minibeam. Because of radiation damage, typically 10u of data was collected using an unattenuated beam, 1u oscillation and 3-10 s exposure before moving to a fresh part of the crystal, if possible, or changing the crystal. Partial data sets from 23 crystals were integrated, scaled and merged together using HKL2000 (ref. 34) . Structure determination and refinement. Initial molecular replacement solution was obtained by Phaser 35 using the receptor domain of the DN-k-OR-T4L-DC/ JDTic structure (PDB accession 4DJH) 5 and the thermostabilized apocytochrome b 562 RIL protein (PDB accession 1M6T) as search models. With two antiparallel receptor molecules in the asymmetric unit of the P2 1 lattice, one of the BRIL domains is disordered whereas the second forms crystal lattice contacts with two receptors from an adjacent layer. We suspect that the disordered BRIL domain is flexible owing to the presence of a flexible linker and the absence of any crystal lattice contacts. The structure was refined by repetitive cycling between Coot 36 and Phenix 37 . The initial stages of refinement were performed with simulated annealing and rebuilding into composite omit maps, and noncrystallographic symmetry and translation/libration/screw (TLS) refinement were implemented throughout. The data collection and refinement statistics are shown in Supplementary Table 5 . Figures were created using PyMOL 38 , and electrostatic surface potentials were obtained using APBS 39 . Molecular modelling of C-24 analogues and UFP-101 peptide binding to NOP. Docking of high-affinity NOP specific ligands was performed using an all-atom flexible receptor docking algorithm in ICM-Pro (MolSoft LLC) molecular modelling package as described previously 40 . Internal coordinate (torsion) movements were allowed in the side chains of the binding pocket, defined as residues within 10 Å distance of C-24 in the crystal structure. Other side chains and the backbone of the protein were kept as in the crystal structure. An initial conformation for small molecule ligands was generated by Cartesian optimization of the ligand model in Merck Molecular Force Field. Docking was performed by placing the ligand in a random position within 5 Å from the entrance to the binding pocket and global conformational energy optimization of the complex 40, 41 . To facilitate side-chain rotamer switches in flexible NOP receptor models, the first 10 6 steps of the Monte Carlo procedure used 'soft' van der Waals potentials and high Monte Carlo temperature, followed by another 10 6 steps with 'exact' van der Waals potentials and gradually decreasing temperature. A harmonic 'distance restraint' was applied between the protonated amine (of piperidine group in the small ligand or Nphe 1 in the UFP-101 peptide) and the carboxyl of the Asp 130 3.32 side chain in the initial 10 6 steps. The restraint was removed in the final 10 6 steps of the docking procedure. With UFP-101, the first six residues Nphe 1-Gly 2-Gly 3-Phe 4-Thr 5-Gly 6 were considered fully flexible, whereas the peptide backbone was fixed in an ideal a-helical conformation for the rest of the peptide (Ala 7-Arg 8-Lys 9-Ser 10-Ala 11-Arg 12-Lys 13-Arg 14-Lys 15-Asn 16-Gln 17). At least 10 independent runs of the docking procedure were performed for each NOP-ligand. The docking results were considered 'consistent' when at least 80% of the individual runs resulted in conformations clustered within an r.m.s.d. of ,1 Å to the overall best energy pose for small molecule ligands and within an r.m.s.d. of ,2 Å for the UFP-101 peptide. All calculations were performed on a 12-core Linux workstation. 
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